Eli Lilly and Company

Amgen Inc.

Imclone LLC

Ling Liu

Jirong Lu

Julian Davies

Ying Tang

Barrett Allan

Peter Edward Vaillancourt

Gunasekaran Kannan

Cen Xu

Edward John Belouski

Haijun Sun

Mark Andrew Wortinger

Jonathan Wendell Tetreault

Chi-Kin Chow

Wei Zeng

Philip Arthur Hipskind

Donmienne Doen Mun Leung

Renhua Li

Lihua Huang

Sheng-Hung Rainbow Tschang

Yiqing Feng

Pia Pauliina Yachi

Jianghuai Xu

Hector Aldaz

Kingman Ng

Takako Wilson

Aaron David Wrobleski

Timothy Wayne Noblitt

Matthew Douglas Breyer

Irene Jennifer Denning

Gregory Beuerlein

Josef Georg Heuer

Zhonghua Qi

Andrew Gordon Werner

Peter Vaillancourt

The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

MET antibody drug conjugates

The present invention relates to methods of using VEGFR1 antibodies for the treatment of chronic kidney disease.

Therapeutic uses for VEGFR1 antibodies

The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.

VEGFR2/Ang2 compounds

Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.

Multifunctional antibodies binding to EGFR and MET

The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.

Anti-c-met antibodies

Provided is a monoclonal antibody, or antigen-binding fragment thereof, that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.

Anti-c-Met antibodies

Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.

c-Met antibodies

The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment

Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.

Anti-IL-17 antibodies

The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antagonist, LP82 polynucleotide, LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

Use of LP82 to treat hematopoietic disorders

Growing community of inventors

Carmel, IN, United States of America

Ling Liu